HighVista Strategies LLC Lowers Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

HighVista Strategies LLC lessened its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 37.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 85,100 shares of the company’s stock after selling 51,400 shares during the period. HighVista Strategies LLC’s holdings in Teva Pharmaceutical Industries were worth $1,534,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Teva Pharmaceutical Industries by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock valued at $11,648,000 after buying an additional 28,071 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Teva Pharmaceutical Industries by 21.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 201,849 shares of the company’s stock worth $2,849,000 after purchasing an additional 36,295 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in Teva Pharmaceutical Industries by 6.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 72,127 shares of the company’s stock valued at $1,036,000 after purchasing an additional 4,131 shares in the last quarter. GAMMA Investing LLC lifted its position in Teva Pharmaceutical Industries by 105.7% during the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after purchasing an additional 1,741 shares during the last quarter. Finally, DNB Asset Management AS grew its stake in shares of Teva Pharmaceutical Industries by 9.6% in the 2nd quarter. DNB Asset Management AS now owns 160,302 shares of the company’s stock worth $2,605,000 after buying an additional 14,001 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.65 on Tuesday. The business has a fifty day moving average price of $17.54 and a 200 day moving average price of $17.36. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TEVA. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays boosted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Finally, UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $19.67.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.